Trinity Partners, a global life sciences consulting firm, today announced that several of its experts are attending the National Organization for Rare Disorders (NORD) Rare Diseases and Orphan Products Breakthrough Summit, taking place October 17 – 18, 2016 in Arlington, VA.
Each year, thought leaders from academia, drug and device companies, patient organizations, government organizations, and more gather at the summit to address the progress and innovations in the diagnosis and management of rare and orphan diseases.
According to NORD, 1 in 10 Americans has a rare disease, which is defined as any condition affecting fewer than 200,000 people in the United States. However, of the roughly 7,000 rare diseases recognized, treatments have only been identified for about five percent.
“Rare diseases represent a large unmet need in the healthcare space,” said Neal Dunn, Head of Primary Research and Partner, Trinity Partners. “My colleagues and I look forward to the opportunity to meet with our peers, better understand the perspective of the patient, and discuss strategies to address the challenges associated with treating and managing these types of diseases.”